Watertown, Mass.-based Enanta Pharmaceuticals and North Chicago, Ill.-based Abbvie are collaborating to develop the drugs, called glecaprevir and pibrentasvir.
The FDA’s breakthrough therapy designation program is intended to accelerate the development and review of an experimental treatment for a serious or life threatening condition when early clinical evidence shows potential for substantial improvement over existing treatment methods.
More articles on supply chain:
Delivery drones decade away from federal approval: 3 things to know
Blood separation technology wins FDA approval
Why EpiPens are so much cheaper in Europe
